Literature DB >> 6176726

Altered pharmacological properties of liposome-associated human interferon-alpha.

D A Eppstein, W E Stewart.   

Abstract

Human interferon-alpha was associated in different ways with positively (stearylamine) and negatively (phosphatidylserine) charged phosphatidylcholine multilamellar vesicles, depending on the presence or absence of a cholesterol component. Inclusion of cholesterol resulted in interferon that was significantly (P = 0.0001) more deeply internalized within the liposomes, such that detergent disruption was necessary before most of the interferon activity was expressed. Interferon was stably associated with stearylamine-containing liposomes, both with and without a cholesterol component. However, inclusion of cholesterol in the phosphatidylserine-containing liposomes was necessary for stable association of the interferon for more than 2 days at 4 degrees C or for more than 24 h at 37 degrees C. After intramuscular injection into mice, liposome-associated interferon in reverse-phase evaporation vesicles was retained at the local site of injection significantly longer than free interferon. Even 3 days after intramuscular injection, stearylamine-containing liposomes with or without cholesterol resulted in local interferon levels that were comparable to the peak levels obtained 2 to 4 h after free interferon was injected. In contrast, free interferon was not detectable in the local muscles 24 h after injection of 10(4.6) U. Liposomes containing phosphatidylserine and cholesterol resulted in intermediate levels of local interferon retention; without a cholesterol component, phosphatidylserine-containing liposomes resulted in no increased local interferon retention compared with the results when free interferon was injected.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176726      PMCID: PMC256786          DOI: 10.1128/JVI.41.2.575-582.1982

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo.

Authors:  H K Kimelberg; M L Atchison
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

Review 2.  Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept.

Authors:  G Gregoriadis
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

3.  In vivo distribution of vesicles loaded with radiopharmaceuticals: a study of different routes of administration.

Authors:  I R McDougall; J K Dunnick; M L Goris; J P Kriss
Journal:  J Nucl Med       Date:  1975-06       Impact factor: 10.057

4.  Use of liposomes for the enhancement of the cytotoxic effects of cytosine arabinoside.

Authors:  E Mayhew; D Papahadjopoulos; Y M Rustum; C Dave
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

5.  Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy.

Authors:  R L Juliano; D Stamp; N McCullough
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

6.  Permeability properties of phospholipid membranes: effect of cholesterol and temperature.

Authors:  D Papahadjopoulos; S Nir; S Oki
Journal:  Biochim Biophys Acta       Date:  1972-06-20

7.  Stability of lipid vesicles in tissues of the mouse: a gamma-ray perturbed angular correlation study.

Authors:  M R Mauk; R C Gamble
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

8.  Tissue distribution of EDTA encapsulated within liposomes of varying surface properties.

Authors:  M M Jonah; E A Cerny; Y E Rahman
Journal:  Biochim Biophys Acta       Date:  1975-09-02

9.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation.

Authors:  F Szoka; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

10.  Enhancement of chemotherapeutic effect by entrapping 1-beta-D-arabinofuranosylcytosine in lipid vesicles and its mode of action.

Authors:  T Kataoka; T Kobayashi
Journal:  Ann N Y Acad Sci       Date:  1978       Impact factor: 5.691

View more
  8 in total

1.  Liposome associated interferon-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig.

Authors:  A Ghahary; E E Tredget; Q Shen; R T Kilani; P G Scott; M Takeuchi
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Pharmacokinetics of an extended-release human interferon alpha-2b formulation.

Authors:  A Bonetti; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection.

Authors:  E B Fraser-Smith; D A Eppstein; M A Larsen; T R Matthews
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

Review 4.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

Review 5.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

6.  Release of human serum albumin from poly(lactide-co-glycolide) microspheres.

Authors:  M S Hora; R K Rana; J H Nunberg; T R Tice; R M Gilley; M E Hudson
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

Review 7.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor.

Authors:  D A Eppstein; Y V Marsh; M van der Pas; P L Felgner; A B Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.